Colorectal cancer (CRC) is the third most common cancer in both men and women in the United States. CRC is suited to population screening in that it is a prevalent disorder with detectable precursor lesions that can be treated. Despite well-established screening recommendations, adherence to CRC screening guidelines is poor. In addition, the U.S. healthcare system does not currently have sufficient resources to provide all the screening services that are required for full adherence to screening guidelines. Conventional CRC screening methods include fecal occult blood testing (FOBT), flexible sigmoidoscopy, and colonoscopy. Recently, the feasibility of screening for CRC by analyzing sequence variants in DNA extracted from fecal specimens has been studied. Several different fecal DNA tests have been proposed that use a variety of markers, including genes associated with chromosomal and DNA instability; aberrant methylation of gene promoter sequences; and the presence of long DNA fragments. The Colosure Colorectal Cancer Detection Test is 1 such test that assesses the methylation status of the vimentin (VIM) gene.